Clinical trials: Stage II Prostate Cancer
Prostate Cancer
Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer
RATIONALE: Implant radiation therapy delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- J-POPS (NCT00534196)
- Testing
- Permanent iodine-125 (Brachytherapy)
- Where
- 31 sites in Japan
- Volunteers
- 6,927 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Breast Cancer, Colorectal Cancer
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
RATIONALE: Identification of genes that may be associated with developing certain types of cancer may someday provide important information about a person's risk of getting cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003329
- Testing
- gene mapping
- Where
- 32 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Eastern Cooperative Oncology Group
Osteoporosis, Prostate Cancer
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer
RATIONALE: Assessing the effect of androgen suppression on bone loss in prostate cancer patients may improve the ability to plan treatment, may decrease the risk of fractures and bony pain, and may help patients live more…
- Trial name
- NCT00003903
- Testing
- management of therapy complications
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Rochester
Prostatic Diseases, Genital Neoplasms, Male
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
The purpose of this research study is to determine the safety and effectiveness of the investigational drug, Ixabepilone, in men with high risk prostate cancer who plan to receive surgery.
- Conditions
- Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Trial name
- NCT00672009
- Testing
- Ixabepilone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Prostate Cancer
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have prostate…
- Trial name
- NCT00016393
- Testing
- ixabepilone
- Where
- 28 sites in United States
- Sponsor
- SWOG Cancer Research Network
Prostatic Neoplasms, Castration-Resistant
Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.
The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant…
- Trial name
- OLIGORESIST (NCT07717268)
- Testing
- Xtandi, Zytiga® (Abiraterone Acetate), SBRT
- Where
- 15 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Calcitriol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. Dexamethasone may help calcitriol work better by making tumor cells more sensitive to the drug.
- Trial name
- NCT00524589
- Testing
- calcitriol, dexamethasone, protein expression analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different way to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perillyl alcohol in treating patients with metastatic…
- Trial name
- NCT00003238
- Testing
- perillyl alcohol
- Where
- 8 sites in United States
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Surgery in Treating Patients With Prostate Cancer
RATIONALE: Prostatectomy may be an effective treatment for prostate cancer that has not responded to radiation therapy. PURPOSE: This phase II trial is studying how well prostatectomy works in treating patients with recurrent or…
- Trial name
- NCT00002938
- Testing
- conventional surgery
- Where
- 61 sites in United States
- Volunteers
- 49 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer
The purpose of this study is to use Sorafenib plus Docetaxel to evaluate pharmacodynamics (PD) in Patients with prostate cancer.
- Trial name
- P1 (NCT00619996)
- Testing
- Sorafenib (Nexavar), Docetaxel
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Italian Trial in Medical Oncology
Metastatic Cancer, Prostate Cancer
Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080678
- Testing
- Docetaxel, Imatinib Mesylate
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00026377
- Testing
- bicalutamide, flutamide, goserelin acetate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Prostate Cancer
Positron Emission Tomography in Prostate Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.
- Trial name
- NCT00121212
- Testing
- carbon-11 acetate PET scan
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Washington University School of Medicine
Male Erectile Disorder, Prostate Cancer
Focal Therapy for Prostate Cancer Using HIFU
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men…
- Conditions
- Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
- Trial name
- INDEX (NCT01194648)
- Testing
- questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation
- Where
- United Kingdom
- Volunteers
- 354 people
- Sponsor
- University College, London
Therapy, Prostatic Neoplasms
Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the safety of docetaxel administered every 3 weeks repeatedly for 11 and more cycles and in combination with daily prednisolone for metastatic hormone refractory prostate cancer.
- Trial name
- NCT00723086
- Testing
- docetaxel (XRP6976)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Sanofi
Prostate Cancer Recurrent, Stage II Prostate Carcinoma
Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer
To development of clinical assessment technique using multi-radiotracer positron emission tomography/magnetic resonance (PET/MR) in prostate cancer to establish the optimal imaging technique of PET/MR using multiple radioactive…
- Conditions
- Prostate Cancer Recurrent, Stage II Prostate Carcinoma, Stage III Prostate Carcinoma
- Trial name
- NCT01938339
- Testing
- PET/MR
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Prostate Cancer, Sexual Dysfunction and Infertility
Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Male hormones can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide and finasteride may fight prostate cancer by reducing the production of male hormones.
- Trial name
- NCT00003323
- Testing
- finasteride, flutamide, quality-of-life assessment
- Where
- 43 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer
RATIONALE: Nerve-sparing radical prostatectomy with nerve grafting followed by standard therapies for erectile dysfunction may be effective in helping patients with prostate cancer improve sexual satisfaction and quality of life.
- Trial name
- NCT00080808
- Testing
- Alprostadil (E1), Papaverine, Phentolamine mesylate
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- M.D. Anderson Cancer Center